Form 8-K - Current report:
SEC Accession No. 0001140361-26-017656
Filing Date
2026-04-29
Accepted
2026-04-29 08:30:47
Documents
15
Period of Report
2026-04-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20071670_8k.htm   iXBRL 8-K 63958
2 EXHIBIT 2.1 ef20071670_ex2-1.htm EX-2.1 722620
3 EXHIBIT 99.1 ef20071670_ex99-1.htm EX-99.1 38331
7 image00002.jpg GRAPHIC 2471
8 image00003.jpg GRAPHIC 1772
  Complete submission text file 0001140361-26-017656.txt   1126583

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA kalv-20260429.xsd EX-101.SCH 3865
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20260429_lab.xml EX-101.LAB 21966
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20260429_pre.xml EX-101.PRE 16044
18 EXTRACTED XBRL INSTANCE DOCUMENT ef20071670_8k_htm.xml XML 4076
Mailing Address 200 CROSSING BOULEVARD FRAMINGHAM MA 01702
Business Address 200 CROSSING BOULEVARD FRAMINGHAM MA 01702 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 26910714
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)